WPI 3699 Pill - white round
Pill with imprint WPI 3699 is White, Round and has been identified as Levetiracetam Extended Release 750 mg. It is supplied by Watson Laboratories, Inc.
Levetiracetam is used in the treatment of Seizures; Epilepsy and belongs to the drug class pyrrolidine anticonvulsants. Risk cannot be ruled out during pregnancy. Levetiracetam 750 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for WPI 3699

Levetiracetam Extended Release
- Imprint
- WPI 3699
- Strength
- 750 mg
- Color
- White
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Pyrrolidine anticonvulsants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Watson Laboratories, Inc.
- National Drug Code (NDC)
- 00591-3699 (Discontinued)
- Inactive Ingredients
-
cellulose acetate,
silicon dioxide,
soya lecithin,
magnesium stearate,
polyethylene glycol 400,
polyethylene glycol 3350,
sodium lauryl sulfate,
magnesium silicate,
titanium dioxide,
ferrosoferric oxide,
propylene glycol
Note: Inactive ingredients may vary.
More about levetiracetam
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (428)
- Drug images
- Latest FDA alerts (6)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: pyrrolidine anticonvulsants
- Breastfeeding
- En español
Patient resources
- Levetiracetam oral/injection drug information
- Levetiracetam Extended-Release Tablets
- Levetiracetam Injection
- Levetiracetam Tablets
- Levetiracetam Oral Solution
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Professional resources
- Levetiracetam monograph
- Levetiracetam (FDA)
- Levetiracetam Extended Release Tablets (FDA)
- Levetiracetam Injection (FDA)
- Levetiracetam Injection, Concentrate (FDA)
- Levetiracetam Solution (FDA)
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.